Encorafenib

• CAT Number: I001079
• CAS Number: 1269440-17-6
• Molecular Formula: C22H27ClFN7O4S
• Molecular Weight: 540.00
• Purity: 98%
• Synonyms: methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate; LGX818
• Target: BRAF
• Target Protein: P15056
• Solubility: in DMSO > 10 mM
• Appearance: Solid
• Storage: Dry, dark and at 2 - 8 °C for six months or -20°C for two years.
• IC50: IC50: 0.3 nM (BRafV600E)
• IUPAC Name: methyl N-[(2S)-1-[[4-[3-[5-chloro-2-fluoro-3-(methanesulfonamido)phenyl]-1-propan-2-ylpyrazol-4-yl]pyrimidin-2-yl]amino]propan-2-yl]carbamate
• InChI: InChI=1S/C22H27ClFN7O4S/c1-12(2)31-11-16(17-6-7-25-21(28-17)26-10-13(3)27-22(32)35-4)20(29-31)15-8-14(23)9-18(19(15)24)30-36(5,33)34/h6-9,11-13,30H,10H2,1-5H3,(H,27,32)(H,25,26,28)/t13-/m0/s1
• InChIKey: CMJCXYNUCSMDBY-ZDUSSCGKSA-N
• SMILES: C[C@@H](CNC1=NC=CC(=N1)C2=CN(N=C2C3=C(C(=CC(=C3)Cl)NS(=O)(=O)C)F)C(C)C)NC(=O)OC

Encorafenib（Cat No.:I001079）is a selective BRAF kinase inhibitor used in combination therapies to treat melanoma and colorectal cancer with BRAF V600E or V600K mutations. By targeting the mutated BRAF protein, Encorafenib disrupts the MAPK/ERK signaling pathway, which is responsible for the uncontrolled growth and proliferation of cancer cells. Its ability to block this pathway slows tumor progression and enhances patient survival. Encorafenib is often combined with other targeted therapies like MEK inhibitors to improve efficacy and reduce resistance, offering an effective treatment for patients with BRAF-mutated cancers.